Open, multi-center randomized research and clinical program MINOTAUROS: intermediate data analysis
Abstract
Aim. To assess indapamide (Arifon retard) effects on blood pressure (BP), carbohydrate, lipid, purine and electrolyte metabolism in patients with mild arterial hypertension (AH) and metabolic syndrome (MS). Material and methods. In total, 573 patients with mild AH and MS participated in MINOTAUROS Study (Patients with MetabolIc SyNdrOme - effecTiveness And ToleRability of ArifOn Retard in Arterial HypertenSion Treatment). All participants were randomized into two groups: 459 were administered Arifon retard and non-pharmaceutical treatment (Group I); 114 patients received only non-pharmaceutical treatment, without pharmaceutical antihypertensive therapy (control Group II). At baseline and after 12 weeks of therapy, BP, body mass (BM), waist circumference (WC), parameters of carbohydrate, lipid, purine, and electrolyte metabolism were measured.. Results. BM and WC decreased in both groups. Arifon retard therapy resulted in greater BP decrease, substantial improvement in carbohydrate and lipid metabolism, with unchanged purine and electrolyte metabolism parameters. Conclusion. Additional beneficial metabolic effects of Arifon retard, as well as its antihypertensive effectiveness, make it a diuretic of choice in treating MS and AH patients.
About the Authors
I. E. Chazova
A.L. Myasnikov Research Institute of Clinical Cardiology, Russian Cardiology Scientific and Clinical Complex, Russian Federal Agency of Health and Social Development. Moscow
Russian Federation
Russian Federation
V. B. Mychka
A.L. Myasnikov Research Institute of Clinical Cardiology, Russian Cardiology Scientific and Clinical Complex, Russian Federal Agency of Health and Social Development. Moscow
Russian Federation
Russian Federation
References
1. Чазова И.Е., Мычка В.Б. Метаболический синдром. Москва «Медиа Медика» 2004; 168 с.
2. Ames RP. Negative effects of diuretic drugs on metabolic risk factors of coronary heart disease: possible alternative drug therapies. Am J Cardiol 1983; 51: 632-8.
3. Беленков Ю.Н., Чазова И.Е., Мычка В.Б. Многоцентровое рандомизированное открытое исследование по изучению эффективности изменения образа жизни и терапии ингибитором АПФ (квинаприлом). Артер гиперт 2003; 9(6): 196-9.
4. Чазова И.Е., Беленков Ю.Н. Первые результаты Российской программы по изучению эффективности применения акарбозы у пациентов с нарушенной толерантностью к глюкозе и артериальной гипертонией (АПРЕЛЬ). Cons Med 2004; 2: 13-8.
5. Houston MC. The Effects of antihypertensive drags on glucose intolerance in hypertensive nondiabetics and diabetics. Am Heart J 1988; 115(3): 640-56.
6. Ames RP, Hill PH. Antihypertensive therapy and risk of coronary heart disease. J Cardiovasc Pharmacol 1982; 4(Suppl.2): S206-16.
7. Bauer JH, Brooks CS, Weidmann I, et al. Effects of diuretic and propranоlol on plasma lipoprotein lipids. Clin Pharmacol Ther 1981; 30: 35-43.
8. Gluck Z, Weidmann P, Mordasini R. Increased serum low-density lipoprotein cholesterol in men, treated short-term with the diuretic chlorthalidone. Metabolism 1980; 29: 240-5.
9. Johnson BF. The emerging problem of plasma lipid changes during antihypertensive therapy. J Cardiovasc Pharmacol 1982; 4(Suppl.2): S213-21.
10. Grimm RH, Grandits GA, Culter JA, et al. Relationships of quality-of-life measures to long-term lifestyle and drug treatment in the treatment of Mild hypertension Study. Arch Intern Med 1997; 157: 638-48.
11. Curb JD, Borhani NO, Blaszkowski TP. Long-term surveillance for adverse effects of antihypertensive drugs. JAMA 1985; 253: 22- 32.
12. Weidmann P. Metabolic profile of indapamide sustained-release in patients with hypertension. Drug safety 2001; 24: 1155-65.
Review
For citations:
Chazova I.E., Mychka V.B. Open, multi-center randomized research and clinical program MINOTAUROS: intermediate data analysis. Cardiovascular Therapy and Prevention. 2006;5(2):81-88. (In Russ.)
Views:
522
Email this article 
